BeAT-HF Trial Results | Barostim™ BAT

Barostim BAT achieves significant and meaningful improvements in heart failure symptoms

+60

Meters

greater 6MHW results with BAT

34^%

Improved

more improved at least 1 NYHA class at 6 months (p<0.001)

-14

Points

improvement in QOL with BAT

Significant reduction in NT-proBNP and collection of morbidity and mortality data

25^%

NT-proBNP

reduction in NT-proBNP with Barostim

1. Zile MR, Abraham WT, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction, J Am Coll Cardiol 2020; 76:1-13

Safe procedures and a potential reduction in serious cardiovascular events

97^%

MANCE-free rate in BAT arm

51^%

*Potential reduction in serious cardiovascular-related hospitalization events with BAT

* https://www.cvrx.com/newsroom/see-the-6-month-data-from-the-beat-heart-failure-study-presented-on-27-may-2019-at-esc-hf/

BeAT–HF trial results

Barostim BAT achieves significant and meaningful improvements in heart failure symptoms

Significant reduction in NT-proBNP and collection of morbidity and mortality data

Safe procedures and a potential reduction in serious cardiovascular events

Read the BeAT-HF JACC publication

Clinical data summary

HRS.20 BeAT-HF data slides

Ready to learn more about Barostim?